New without opioids painkiller On Thursday, she approved the US Food and Medicines Directorate (FDA), which indicated a non -disposing alternative for patients.
Journavx (Suzetrigine), made Vertex, “the first and only approved non-oioid oral pain inhibitor,” the company based in Massachusetts said.
The new drug is intended for the treatment of moderate to severe acute pain in adults.
The importance of an alternative not opioid
Often prescribed patients with acute pain or because of a broken bone or injury opioid drugsAccording to Ph.D. Julie Pilis, MD, neurosurgeon at Banner – University Medicine and Chairman of the Department of Neurosurgery at the Faculty of Medicine, University of Arizona in Tucson.
The new Opioid FDA paint -free drug was approved on Thursday, marking a non -disposing alternative for patients. (East)
“This is the first time many patients are receiving opioids, and it is known that the patient’s subset becomes dependent or dependent drugs, “she told Fox News Digital.
“Patients with pain have had very little ability to treat their pain with drugs that do not have addiction or side effects that cannot be tolerated.”
6 of the most common type of headache – and when to visit a doctor
The main reason why traditional pain relief have addiction or unbearable side effects is that they act by modifying the receptors in the brain, the pilis noted.
“This medicine – which is a cure that inhibits sodium channels – works outside the brain on the receptors of pain,” she noticed.
“It is exciting to have a non-life possibility to prescribe in these cases, this is the first time in almost two decades that we have something new for acute pain.”
‘The main dissatisfied need’
Acute pain – sudden or urgent pain resulting from injury, trauma or surgery – affects more than 80 million Americans a year and is the most common reason for Emergency Department Visit, according to statistics.
About half of them will be prescribed by opioid, and 10% of those will have an “prolonged use of opioids”.
Acute pain – sudden or emergency pain that is a consequence of injury, trauma or surgery – affects more than 80 million Americans a year and is the most common reason for visiting the ambulance department. (East)
In 2023, more than five million Americans 12 and older reported a “prescription use disorder” last year, according to the centers for the control and prevention of the disease (CDC).
Approximately 294,000 people died overdose Between 1999 and 2022.
Effectively managing acute pain, Suzetrigina can help prevent it from developing into chronic pain without the danger of addiction, fulfilling the “main disgusted need,” noted Jianguo Cheng, MD, doctorate, a professor for pain management at Cleveland Clinic.
“This is the first time in almost two decades that we have something new to offer patients for acute pain.”
“Many current therapies rely on opioids, contributing to addiction and abuse,” Fox News Digital told Fox News. “Suztrigine’s non-Oioid mechanism eliminates the risk of abuse, addictions and respiratory depressionwhich makes it a safer alternative to acute pain management. “
In addition to acute pain, Suzetrigin may also be a solution for neuropathic (nerve) pain, depending on the results of further studies, the doctor added.
In addition to acute pain, Suzetrigin may also be a solution for neuropathic (nervous) pain, depending on the results of further studies, the doctor noted. (East)
Dr. Marc Siegel, a clinical professor of medicine in Nyu Langon Health and Fox News, a senior medical analyst, also applauded Suztriginal approval.
Click here to get the Fox News app
“There is There is no sign of addictionwhich makes him an extremely important new tool while fighting the epidemic of Opioid, “he told Fox News Digital.
In clinical trials, non-theid drugs have received high patients’ satisfaction assessments, and 83% have reported “good” to “excellent” pain relief in the real world, Cheng noted.
“This medicine is a big step forward and is well studied.”
Siegel noted that the drug showed that it reduced pain by about half, which he described as “excellent”.
“This medicine is a big step forward and it is well studied,” he added.
Access and side effects
Suzetrigine has become available for patients with acute painnoted Pilitsis.
“It will be important to find doctors who comfortably prescribe painkillers and check with the insurance company to ensure that it is covered,” she advised.
Click here to sign up for our Health Bulletin
The drug is expected to fall under opioids prevents addiction in the Nation Law (Nopain), in force on January 2025, which provides the coverage of Medicare for non-oioidal therapies without opioids, Cheng said.
“This policy aims to improve approach and accessibility, ensuring the inclusion of suppricine in the ambulance and surgical settings As he reduced his reliance on opioids, “he said.
In 2023. More than five million Americans 12 and older reported “prescription use disorder” last year, per CDC. (East)
The most common side effects of Journavx, according to the company website, include itching, muscle cramps, rashes and increased levels of enzyme called creatine phosphokinase in the blood.
The drug can also cause temporary fertility challenges.
For more health articles visit www.foxnews.com/health/health
Certain medicines can increase the risk of side effects and affect the effectiveness of the drug, the company warned, as well as food or drink containing grapefruit.
Patients should see their doctor if any side effects become painful or disappear.
Fox News Digital reached out to Vertex for additional comments.
